Hemostasis Market Report and Forecast 2025-2034

The global hemostasis market was valued at USD 3.70 Billion in 2024, driven by the growing number of surgical procedures across the globe. The market is anticipated to grow at a CAGR of 3.40% during the forecast period 2025-2034 to reach a value of USD 5.17 Billion by 2034.

Hemostasis Market Overview

Hemostasis is the body’s reaction to heal an injury that caused bleeding in the first place. The capability of the body to heal itself plays a vital role in the survival of a person. The reaction is a combination of multiple processes coming together to heal a wound. The market for hemostasis is driven by the rising incidence of surgical procedures, new product launches developed using innovative materials and the rising prevalence of accidents on a global scale. Conditions like hemophilia and von Willebrand disease are driving the need for advanced hemostasis solutions, leading to increased R&D for better treatments.

Hemostasis Market Growth Drivers

Rising Surgical Procedures Contributing to Rising Demand for Hemostasis Management

The market growth can be attributed to the escalating number of surgeries across several fields including cardiovascular and trauma surgeries. As per the data published by the Annals of Thoracic Surgery Short Reports, the average cardiac surgical volume is around 123.2 surgeries per 100,000 population per year in high-income countries. Similarly, surgeries for other chronic diseases are increasing, creating a high demand for hemostasis agents, and stimulating market growth.

Increasing Approvals to Meet Rising Hemostasis Market Demand

The market growth is poised to be driven by the increasing FDA approvals, enabling the availability of multiple hemostasis solutions contributing to enhanced patient outcomes. For instance, in November 2023, Ethicon, a Johnson & Johnson MedTech company, announced the approval of ETHIZIATM, an adjunctive hemostasis solution that has been clinically proven to achieve sustained hemostasis in difficult-to-control bleeding situations. ETHIZIA™ Hemostatic Sealing Patch is comprised of unique synthetic polymer technology and is the first and only hemostatic matrix designed to be equally active and efficacious on both sides.

Additionally, in April 2024, Haemonetics Corporation, a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adult cardiovascular surgeries/procedures and liver transplantation in both laboratory and point-of-care settings. This product launch is expected to assist physicians in improving hemostasis management for their patients, especially in critical situations like open heart and liver transplant surgeries and major trauma. The FDA clearance is also projected to make effective and efficient viscoelastic testing more accessible, contributing to market expansion.

Hemostasis Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Technological Advancements

The market is experiencing growing adoption of point-of-care (POC) testing and automated devices, improving accuracy and speed in diagnosing and managing bleeding disorders. These advanced devices are poised to bring innovation to the hemostasis landscape.

Product Launches Propelling Market Growth

One of the major market trends involves new product launches. For instance, in July 2024, Baxter International Inc., a global leader in advancing surgical innovation launched PERCLOT Absorbable Hemostatic Powder in the United States. PERCLOT is a passive, absorbable hemostatic powder designed to be used by patients with intact coagulation to address mild bleeding. New product launches are poised to fuel market growth, contributing to enhanced patient outcomes.

Advanced Hemostatic Agents

With rising surgical procedures and trauma cases, the demand for advanced hemostatic agents, such as tissue sealants and fibrin adhesives, is increasing globally. Key players are developing novel products such as fibrin sealants, collagen-based agents, gelatin sponges, and synthetic sealants. These products offer rapid clotting and tissue adhesion properties, enhancing surgical outcomes.

Growth in Minimally Invasive Surgeries

There is a growing preference for minimally invasive surgeries driven by its faster recovery times and reduced complications. With more minimally invasive surgeries being performed, specialised hemostatic products that aid in faster recovery and reduced blood loss are in higher demand.

Hemostasis Market Segmentation

Market Breakup by Product Type

• Topical Hemostasis Products
• Gelatin-based Hemostats
• Collagen-based Hemostats
• ORC-based Hemostats
• Polysaccharide-based
• Infusible Hemostasis Products
• Platelet Concentrate
• Fresh Frozen Plasma
• Factor VIII
• Prothrombin
• Advanced Hemostasis Products
• Flowable
• Thrombin
• Synthetic Sealants
• Fibrin

Market Breakup by Application

• General Surgery
• Neurosurgery
• Vascular Surgery
• Cardiovascular Surgery
• Others

Market Breakup by End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Hemostasis Market Share

Market Share Based on Application to Witness Substantial Growth

The market segmentation by application is categorised into general surgery, neurosurgery, vascular surgery, cardiovascular surgery, and others. The market share is dominated by general surgeries due to the high incidence worldwide. Hemostatic management plays a vital role in surgical procedures to control the blood flow and avoid excessive bleeding during and after the procedures. These hemostat agents have common applications in advanced surgical procedures that necessitate effective tissue-sealing agents to eliminate or reduce complications and result in improved patient outcomes. The similar nature of collagen-based hemostats to the collagen in the tissue makes them a preferred option to be used in these surgeries.

Hemostasis Market Analysis by Region

North America is dominating the market share by region due to the rising cases of excessive bleeding and the need to bring new solutions for hemostasis management. The market is poised to be driven by the presence of a robust healthcare infrastructure, enabling the availability of technically advanced management solutions. Further, the presence of some of the key players in the region is stimulating market growth. The region leads the hemostats market due to significant healthcare expenditure, and the presence of major pharmaceutical and medical device companies that are focused on bringing innovation into the market.

The region experiences a high volume of surgical procedures, and trauma cases, and also holds a significant share of the geriatric population contributing to increased demand for hemostatic products. Additionally, strong regulatory frameworks and rapid adoption of advanced medical technologies, such as minimally invasive surgical tools and point-of-care hemostasis testing, further fuel the market. The regional dominance is also attributed to the continuous focus on product innovation and widespread insurance coverage supporting growth in the market.

Leading Players in the Hemostasis Market

The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:

Medtronic PLC

Medtronic offers a range of hemostatic products, including advanced surgical sealants, topical agents, and mechanical haemostats. Its portfolio focuses on managing bleeding during surgeries, enhancing wound healing, and improving patient recovery through innovative medical technologies across cardiovascular, neuro, and general surgeries.

Johnson & Johnson Inc.

Johnson & Johnson, through its subsidiary Ethicon, provides a comprehensive portfolio of hemostatic products including SURGIFLO®, SURGICEL®, and EVARREST®. These products are designed to control bleeding in surgical settings, ensuring rapid hemostasis and improved patient outcomes across various surgical procedures.

Baxter International Inc.

Baxter is a key player in the hemostasis market, offering products like Floseal® and Tisseel®. These haemostatic agents are used in surgical procedures to control bleeding, combining biological and mechanical hemostasis for optimal surgical outcomes, supporting vascular, orthopaedic, and general surgery applications.

Pfizer

Pfizer's presence in the hemostasis market is primarily through its biologics division, offering recombinant clotting factors, such as BeneFIX®, for the treatment of haemophilia. The company focuses on therapies that enhance blood clotting for patients with clotting disorders, supporting both surgical and non-surgical applications.

BD

BD focuses on hemostasis through its range of vascular access devices, blood collection systems, and point-of-care diagnostics. Its products help manage blood flow, improve blood sampling, and enhance patient safety in various clinical settings, from surgery to emergency care.

Other key players in the market include B. Braun SE, Tricol Biomedical, Boston Scientific Corporation, Cura Medical, and Teleflex Incorporated.

Key Questions Answered in the Hemostasis Market

• What was the global hemostasis market value in 2024?
• What is the global hemostasis market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is market segmentation based on product type?
• How is the market segmented based on the application?
• Who are the end-users in the market?
• What are the major factors aiding the global hemostasis market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major global hemostasis market trends?
• Which product type will dominate the market share?
• Which application is poised to lead the market share?
• Which end-user will lead the market?
• Who are the key players involved in the global hemostasis market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.